Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect

R. V. La Rocca, C. A. Stein, R. Danesif, Carlos Alberto Jamis-Dow, G. H. Weiss, C. E. Myers

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 μg/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3–10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma.

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume71
Issue number2
DOIs
StatePublished - Jan 1 1990

Fingerprint

Adrenal Gland Neoplasms
Steroid hormones
Suramin
Adrenocortical Carcinoma
Cytotoxicity
Steroids
Modulation
Hormones
Cells
Cell Line
Antiparasitic Agents
Mineralocorticoids
Proxy
Adrenal Glands
Aldosterone
Primates
Glucocorticoids
Androgens
Tumors
Down-Regulation

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

La Rocca, R. V. ; Stein, C. A. ; Danesif, R. ; Jamis-Dow, Carlos Alberto ; Weiss, G. H. ; Myers, C. E. / Suramin in adrenal cancer : Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. In: Journal of Clinical Endocrinology and Metabolism. 1990 ; Vol. 71, No. 2. pp. 497-504.
@article{5aea616bb479492596400beb9750ce15,
title = "Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect",
abstract = "Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 μg/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3–10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma.",
author = "{La Rocca}, {R. V.} and Stein, {C. A.} and R. Danesif and Jamis-Dow, {Carlos Alberto} and Weiss, {G. H.} and Myers, {C. E.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1210/jcem-71-2-497",
language = "English (US)",
volume = "71",
pages = "497--504",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

Suramin in adrenal cancer : Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. / La Rocca, R. V.; Stein, C. A.; Danesif, R.; Jamis-Dow, Carlos Alberto; Weiss, G. H.; Myers, C. E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 71, No. 2, 01.01.1990, p. 497-504.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suramin in adrenal cancer

T2 - Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect

AU - La Rocca, R. V.

AU - Stein, C. A.

AU - Danesif, R.

AU - Jamis-Dow, Carlos Alberto

AU - Weiss, G. H.

AU - Myers, C. E.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 μg/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3–10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma.

AB - Suramin, a drug known to have antiparasitic effects, has been previously shown to have adrenocorticolytic activity in primates. We now confirm preferential accumulation of this compound in the normal adrenal gland, evaluate its in vitro effect against two human adrenocortical carcinoma cell lines (SW-13 and NCI-H295), and report the clinical activity of suramin in 17 patients with metastatic adrenocortical carcinoma. Inhibition of colony formation occurred in both adrenal cell lines in vitro at concentrations that are clinically achievable in humans. In addition, suramin concentrations as low as 100 μg/mL were able to inhibit glucocorticoid, mineralocorticoid, and androgen production by the NCI-H295 cell line. Of 16 patients with adrenocortical carcinoma now evaluable for tumor response, 2 achieved a partial response, 2 had a minor response, and 5 remained with stable disease for periods ranging from 3–10 months; the remainder progressed. One of 7 patients with excessive steroid hormone production achieved a partial normalization of her steroid levels for the duration of suramin therapy in the setting of radiographic disease stabilization. An additional patient treated off-study for lack of radiographically measurable disease, achieved complete normalization of plasma aldosterone levels. We conclude that suramin preferentially accumulates in adrenal cells, induces cytotoxicity and significant down-regulation of steroid hormone production in vitro, and has some therapeutic efficacy as a single agent in patients with metastatic adrenocortical carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0025079187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025079187&partnerID=8YFLogxK

U2 - 10.1210/jcem-71-2-497

DO - 10.1210/jcem-71-2-497

M3 - Article

C2 - 2380344

AN - SCOPUS:0025079187

VL - 71

SP - 497

EP - 504

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -